Loading…
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-31M | $-46M | $-24M | -195.3% | 257.1% | - |
| 2024 | $0M | $-43M | $-42M | $-33M | -131.1% | -91.0% | - |
| 2023 | $0M | $-30M | $-30M | $-12M | -78.7% | -58.6% | - |
| 2022 | $0M | $-26M | $-27M | $-23M | -45.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.37 | 0.15 | 0.01 | 0.05 |
| Operating Expense | 26.32 | 29.90 | 42.65 | 30.92 |
| Operating Income | -25.95 | -29.74 | -42.63 | -30.87 |
| EBITDA | -25.95 | -29.74 | -42.63 | -30.79 |
| EBIT | -25.95 | -29.74 | -42.63 | -30.87 |
| Pretax Income | -27.30 | -30.01 | -42.08 | -45.93 |
| Net Income | -27.30 | -30.01 | -42.08 | -45.93 |
| Net Income Common Stockholders | -27.30 | -30.01 | -42.08 | -45.93 |
| Total Expenses | 26.32 | 29.90 | 42.65 | 30.92 |
| Research And Development | 17.07 | 20.27 | 33.17 | 20.66 |
| Selling General And Administration | 9.26 | 9.62 | 9.48 | 10.26 |
| Normalized EBITDA | -25.95 | -29.74 | -42.63 | -14.27 |
| Normalized Income | -27.30 | -30.01 | -42.08 | -29.42 |
| Basic EPS | -1.52 | -1.67 | -2.11 | 0 |
| Diluted EPS | -1.52 | -1.67 | -2.11 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | -16.51 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | -16.51 |
| Net Income From Continuing Operation Net Minority Interest | -27.30 | -30.01 | -42.08 | -45.93 |
| Reconciled Depreciation | 0 | 0 | 0 | 0.08 |
| Net Income From Continuing And Discontinued Operation | -27.30 | -30.01 | -42.08 | -45.93 |
| Total Operating Income As Reported | -25.95 | -29.74 | -42.63 | -47.38 |
| Diluted Average Shares | 17.93 | 17.98 | 19.94 | 0 |
| Basic Average Shares | 17.93 | 17.98 | 19.94 | 0 |
| Diluted NI Availto Com Stockholders | -27.30 | -30.01 | -42.08 | -45.93 |
| Net Income Including Noncontrolling Interests | -27.30 | -30.01 | -42.08 | -45.93 |
| Net Income Continuous Operations | -27.30 | -30.01 | -42.08 | -45.93 |
| Other Income Expense | -1.35 | -0.27 | 0.55 | -15.06 |
| Other Non Operating Income Expenses | -1.35 | -0.27 | 0.55 | 1.45 |
| Special Income Charges | 0 | 0 | 0 | -16.51 |
| Impairment Of Capital Assets | 0 | 0 | 0 | 16.51 |
| General And Administrative Expense | 9.26 | 9.62 | 9.48 | 10.26 |
| Other Gand A | 9.26 | 9.62 | 9.48 | 10.26 |
| Operating Revenue | 0.37 | 0.15 | 0.01 | 0.05 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| INmune Bio Inc.this co. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 |
| -99.8% |
| -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 | -2.0% | -107.66 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 0.93 | -93.4% | -1.64 | |